Clinical trials: Flu
Influenza B
Dose, Safety, and Pathogenicity of a New Influenza B Strain
This is an exploratory study of an influenza B challenge strain to determine the optimum infectious titer of challenge agent in healthy participants 18 to 55 years of age.
- Trial name
- NCT06254820
- Testing
- influenza B/Connecticut/1/21 virus part a dose arm 1, influenza B/Connecticut/1/21 virus part a dose arm 2, influenza B/Connecticut/1/21 virus part b dose 1
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Hvivo
Haemophilus Influenza Type b
Exploratory Clinical Study of MT-2301
The purpose of this study is to evaluate efficacy and safety of MT-2301 when co-administered with DPT-IPV using ActHIB® as a control in healthy infants.
- Trial name
- NCT02140047
- Testing
- Haemophilus b conjugate vaccine diphteria CRM197 protein conjugate)-Low + DPT-IPV, Haemophilus b conjugate vaccine diphteria CRM197 protein conjugate)-High + DPT-IPV, Haemophilus influenza type b conjugate vaccine + DPT-IPV
- Where
- Japan
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma Corporation
Influenza, COVID-19
Flu COVID Vaccine Views
This study addresses a critical evidence gap relevant to implementation strategies for combination vaccines in health care settings.
- Conditions
- Influenza, COVID-19, Vaccination Willingness
- Trial name
- NCT07871448
- Testing
- Survey
- Where
- 2 sites in United States
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- George Washington University
Influenza, Orthomyxoviridae Infections
Study of Different Formulations of an Intramuscular A/H5N1 Inactivated, Split Virion Influenza Adjuvanted Vaccine
Following the licensure of sanofi pasteur's 90 µg rgA/Vietnam/1203/2004 pandemic influenza vaccine, efforts to develop a lower antigen dose formulation with improved immunogenicity using adjuvants were initiated.
- Trial name
- NCT00664417
- Testing
- Monovalent subvirion H5N1 influenza vaccine, Physiological saline
- Where
- 6 sites in United States
- Volunteers
- 375 people, healthy volunteers welcome
- Sponsor
- Sanofi
Influenza
Safety and Immunogenicity of A/H1N1v Vaccines in Healthy Adults
The purpose of this study is to evaluate the antibody response to one and two doses of influenza A/H1N1v vaccine in healthy adults.
- Trial name
- NCT00943358
- Testing
- MF59 H1N1 vaccine, Plain H1N1 vaccine
- Where
- United Kingdom
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- University Hospitals, Leicester
Influenza
Immunogenicity and Safety of AdimFlu-S 2011-2012 in Non-Elderly Adult and Elderly Subjects
The purpose of this study is to evaluate the antibody response to each of the three influenza vaccine strains included in the licensed seasonal flu vaccine, as measured by hemagglutination inhibition (HAI) at 21 days post…
- Trial name
- NCT01411358
- Testing
- non-elderly aged between 18 and 60, elderly aged over 60
- Where
- Taiwan
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Adimmune Corporation
Vaccine Reaction
Intradermal Influenza Vaccination- Healthy Cohort
The goal of this study is to characterize the immune response, both innate and adaptive, as well as locally and systemic, to intradermal (ID) vaccination in healthy individuals compared to intramuscular vaccination and placebo.
- Trial name
- NCT06067555
- Testing
- MicronJet, Fluzone® Quadrivalent, Bacteriostatic Saline
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Yale University
Influenza
Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age
The purpose of this study is to assess the immunogenicity and safety of GSK Biologicals' quadrivalent influenza vaccine (GSK2282512A) compared to Sanofi Pasteur's Fluzone® Quadrivalent in children 6 to 35 months of age.
- Trial name
- NCT02242643
- Testing
- FluLaval™ Quadrivalent, Fluzone® Quadrivalent
- Where
- 66 sites in United States, Mexico
- Volunteers
- 2,432 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Immune Response
Immune Response Analysis to Influenza Vaccine in Elderly Aged Over 65 Years
This study is the first step in a clinical research program that aims to study the immune response to influenza vaccine in the elderly and then to propose a new method of administering the vaccine.
- Trial name
- Expand IDWP21 (NCT01289535)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Influenza
Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults
The objective of the study is to evaluate the immunogenicity and safety of GSK Biologicals' investigational vaccine GSK2340272A.
- Trial name
- NCT00968526
- Testing
- GSK investigational vaccine GSK2340272A
- Where
- Belgium
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
A Study to Evaluate Safety and Immunogenicity of FluvalAB-like Influenza Vaccine in Non-Elderly Adult and Elderly Subjects
The purpose of this study is to determine the immunogenicity and tolerability of one 0.5 mL intramuscular (IM) injection of FLUVAL AB-like trivalent influenza vaccine containing 6μgHA of seasonal A/H1N1, A/H3N2 and B influenza…
- Trial name
- NCT01459276
- Testing
- Vaccination with FAB-6011, Vaccination with FluvalAB
- Where
- 7 sites in Hungary
- Volunteers
- 1,206 people, healthy volunteers welcome
- Sponsor
- Fluart Innovative Vaccine Ltd, Hungary
Influenza
Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine in Elderly People
The purpose of the study is to evaluate the safety of GSK Biologicals' influenza vaccine. Elderly subjects were randomized in the primary study (NCT00760617) and will now receive the same vaccine for the third time.
- Trial name
- NCT00992784
- Testing
- GSK investigational vaccine 2186877A, FluarixTM
- Where
- 24 sites in Germany, Netherlands and 1 more
- Volunteers
- 370 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Trial to Describe the Safety and Immunogenicity of Fluzone®
Objective 1:To describe the safety of the inactivated, split-virion influenza vaccine, Northern Hemisphere (NH) 2007-2008 formulation.
- Trial name
- NCT00524940
- Testing
- Inactivated, Split-Virion Influenza Virus
- Where
- United States
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Sepsis, Viral Pneumonia
Discover the Immune Signature of Sepsis Caused by Acute Pulmonary Infection: A Cohort Study
The goal of this observational study is to describe the immune signature of acute pulmonary infection.The main questions it aims to answer are: 1. Nasal mucosal immune response in patients with influenza infection 2.
- Conditions
- Sepsis, Viral Pneumonia, Influenza, Upper Respiratory Tract Infection
- Trial name
- DISPLAY (NCT05612893)
- Testing
- pathogen
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Capital Medical University
Influenza, Pneumonia
Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years
The overall objective of this study is to describe the effectiveness of Flublok Quadrivalent vaccine compared to standard dose inactivated influenza vaccine (SD-IIV) in adults 18 through 64 years of age.
- Conditions
- Influenza, Pneumonia, Lower Respiratory Tract Infection, Acute Myocardial Infarction
- Trial name
- NCT03694392
- Testing
- Flublok Quadrivalent, Standard Dose Inactivated Influenza Vaccine (SD-IIV)
- Where
- United States
- Volunteers
- 2,776,278 people, healthy volunteers welcome
- Sponsor
- Kaiser Permanente
Influenza
Safety and Immunogenicity Study of GSK Biologicals' Seasonal Influenza Candidate Vaccine (GSK2321138A)
This study is designed to assess the safety and immunogenicity of a GSK Biologicals' investigational vaccine GSK2321138A in adults 18 years old and older.
- Trial name
- NCT01204671
- Testing
- Influenza vaccine GSK2321138A, FluarixTM, Influenza vaccine GSK2604409A
- Where
- 42 sites in United States, Germany and 4 more
- Volunteers
- 4,659 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Outcomes of Pandemic Influenza in Pregnancy
We propose to follow a cohort of pregnant and post-partum Canadian women through the fall and winter of 2009/2010 and the anticipated second and third waves of the current pandemic in order to better understand the incidence…
- Trial name
- NCT01322516
- Where
- 8 sites in Canada
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Dalhousie University
Influenza
Prospective Cohort Study to Evaluate Safety/Immunogenicity of Butantan Influenza Vaccine in Healthy Adults/Elderly
Prospective cohort study to evaluate safety and immunogenicity of the fragmented, inactivated trivalent Influenza vaccine produced at Butantan Institute in healthy adults and elderly.
- Trial name
- NCT02313740
- Testing
- Butantan Fragmented Inactivated Trivalent Influenza Vaccine
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Healthy, Elderly
Safety of Lactobacillus Rhamnosus GG Vs. Placebo in Elderly Subjects Receiving Trivalent Inactivated Influenza Vaccine
This is a phase I, randomized controlled trial to evaluate the safety of Lactobacillus rhamnosus GG (LGG) versus placebo in elderly subjects receiving the trivalent inactivated influenza vaccine.
- Trial name
- NCT01368029
- Testing
- Lactobacillus rhamnosus GG ATCC 53103 (LGG)
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Immunology
Impact of Egg-Based and Cell-Based Vaccine Platforms on Immune Responses to Repeated Influenza Vaccination
The goal of this clinical trial is to learn how different types of influenza (flu) vaccines affect the body's immune response over time.
- Trial name
- NCT07910266
- Testing
- Egg-Based Inactivated Influenza Vaccine, Cell-Based Inactivated Influenza Vaccine
- Where
- United States
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- University of Missouri-Columbia
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.